A copper-delivering compound has done something researchers have been chasing for decades: it cleared nearly half of the toxic proteins that drive Alzheimer’s disease, repaired the brain’s own waste-removal system, and restored memory, all within a single preclinical study.
The research, published June 15, 2026, in the journal ACS Chemical Neuroscience by scientists at Monash University’s Monash Institute of Pharmaceutical Sciences, found that a compound called Cu(ATSM) reduced toxic amyloid-beta proteins by 42% and improved spatial learning by nearly 44% over just 56 days of treatment in laboratory models of Alzheimer’s disease.
What makes this finding especially significant is that Cu(ATSM) is not a new, untested molecule sitting in a lab freezer somewhere.
It has already passed safety evaluations in humans for other neurological diseases, including Parkinson’s disease and ALS.
That means, if the results hold up in further studies, the path to human trials for Alzheimer’s could move faster than usual.
For the more than 7.4 million Americans currently living with Alzheimer’s, and the tens of millions more worldwide watching a loved one decline, that distinction matters enormously.
To understand why this finding is so important, you need to know what Alzheimer’s actually does to the brain at a plumbing level.
The human brain constantly produces waste.
One of the most dangerous byproducts is a sticky, toxic protein called amyloid-beta.
Under normal conditions, the brain has a highly efficient system for flushing amyloid-beta out: it pushes it across the blood-brain barrier and into the bloodstream, where the body can dispose of it.
The key players in this flush mechanism are proteins called P-glycoprotein pumps, sometimes shortened to P-gp.
Think of them as tiny drain valves at the border between the brain and the bloodstream, constantly working to push toxic waste out of the brain.
In people with Alzheimer’s, these pumps weaken and break down.
The drain clogs. Amyloid-beta begins to accumulate, forming the plaques that clog the brain, destroy neurons, and gradually steal memory, language, and identity.
Scientists have known for years that dysfunctional blood-brain barrier clearance is a central feature of Alzheimer’s disease.
What they have not been able to do, until now, is find a way to fix it.
How the Study Was Conducted
The Monash University team tested Cu(ATSM) using the APP/PS1 mouse model, which is a widely used laboratory model that replicates key features of familial Alzheimer’s disease, including the buildup of amyloid-beta in the brain.
The researchers administered Cu(ATSM) to the mice and tracked what happened to their brain biology and behavior over a 56-day treatment period.
The team measured three key outcomes.
First, they looked at whether the drug changed the abundance of P-glycoprotein pumps at the blood-brain barrier.
Second, they measured how much amyloid-beta remained in the brain after treatment.
Third, they assessed cognitive function using standard tests of spatial learning and memory.
The study was led by Dr. Jae Pyun from the Drug Delivery, Disposition and Dynamics theme at MIPS, working under senior author Professor Joseph Nicolazzo, the director of the Centre for Drug Candidate Optimisation at MIPS.
Findings From the Study
The results were striking across every measure the researchers tracked.
P-glycoprotein pump abundance increased by 24.1%. This was the first time any study had demonstrated that Cu(ATSM) could boost the number of these critical clearance pumps in an Alzheimer’s model.
Toxic amyloid-beta in the brain dropped by 42%. With the pumps working better, the brain’s waste-removal system could once again push the toxic proteins out.
Spatial learning improved by nearly 44%. As the toxic burden fell, cognitive function recovered in measurable, meaningful ways.
These three outcomes formed a clear chain of cause and effect: fix the pumps, clear the waste, restore the memory.
Professor Nicolazzo noted that the compound has strong potential to transition quickly into human clinical testing precisely because it has already cleared safety hurdles for other diseases.
The researchers also believe the copper treatment may be doing something else under the surface.
Beyond repairing the blood-brain barrier, they suspect Cu(ATSM) activates microglia, the brain’s resident immune cells, encouraging them to consume and break down the toxic plaques directly.
That parallel mechanism is still being investigated, and future studies will focus on tracking the exact routes these proteins take as they leave the brain.
Most conversations about Alzheimer’s drugs focus entirely on destroying amyloid plaques directly.
The logic sounds obvious: the plaques are the problem, so attack the plaques.
That approach has driven billions of dollars of pharmaceutical investment over the past two decades, and it has produced some real breakthroughs, including drugs like lecanemab and donanemab, which use antibodies to clear existing plaques from the brain.
But there is a quieter and arguably more fundamental problem that those drugs do not solve.
If the brain’s own clearance system stays broken, amyloid-beta will simply keep building up again.
You can mop the floor all day, but if you do not fix the leaking pipe, the water will keep coming.
Cu(ATSM) takes a different approach entirely.
Instead of targeting the amyloid-beta proteins themselves, it targets the system that was supposed to remove them in the first place.
It repairs the pipe.
This matters because neurovascular dysfunction, meaning the breakdown of the blood vessels and barrier systems in the brain, is increasingly recognized as a major driver of Alzheimer’s, not just a side effect of it.
A growing body of research suggests that blood-brain barrier damage may actually begin before the amyloid plaques become visible on scans, meaning the plumbing breaks first, and then the toxic proteins accumulate as a consequence.
If that is true, then fixing the clearance system could be one of the most important interventions possible in early Alzheimer’s disease, perhaps even before symptoms appear.
How the Study Applies to Real Life
This was a preclinical study conducted in mice, and that context matters.
Many compounds that produce dramatic results in animal models do not survive contact with human biology.
The researchers are clear about this, and the science is honest about the distance still to travel.
But Cu(ATSM) carries an unusual advantage that most experimental Alzheimer’s drugs do not have.
Because it has already been tested in humans for Parkinson’s disease and ALS, scientists already have data on how the compound behaves in a living human body, what doses it tolerates, how it crosses the blood-brain barrier, and what side effects it may produce.
That existing safety profile dramatically shortens the early phases of clinical development.
It means researchers do not have to start from zero with Phase I safety trials in the way they would with an entirely novel molecule.
According to the Alzheimer’s Association’s 2026 Facts and Figures report, an estimated 7.4 million Americans aged 65 and older are currently living with Alzheimer’s, a number that will continue to grow as the population ages.
Health and long-term care costs for people with Alzheimer’s and other dementias are projected to reach $409 billion in 2026 alone.
Globally, the picture is even more sobering.
The worldwide prevalence of Alzheimer’s and related dementias among adults aged 65 and older increased by 160% between 1991 and 2021, rising from roughly 18.7 million cases to nearly 49 million.
In Australia, dementia has already overtaken coronary heart disease to become the nation’s leading cause of death, a grim milestone that underscores the urgency driving researchers like the Monash team.
Why Copper?
The role of copper in brain health is not a new area of interest, but it has long been overshadowed by flashier targets.
Copper is an essential mineral that the brain depends on for a wide range of functions, from energy production in neurons to the regulation of oxidative stress.
Cu(ATSM), which stands for copper diacetyl bis(4-methyl-3-thiosemicarbazone) in its full chemical name, was developed as a way to safely deliver copper into the brain across the blood-brain barrier.
The compound has anti-inflammatory and neuroprotective properties, and its ability to reach the brain makes it particularly well-suited to targeting the kind of vascular dysfunction seen in Alzheimer’s disease.
It is worth noting that this is not a case of someone deciding copper supplements might help with dementia.
This is a precisely engineered pharmaceutical compound designed to carry copper to a specific biological target and trigger a specific chain of biological events.
The distinction between a dietary supplement and a targeted therapeutic is enormous.
What Comes Next
The Monash team is now focused on understanding the exact mechanisms by which amyloid-beta leaves the brain following Cu(ATSM) treatment.
Repairing the P-gp pumps explains part of the story, but the 42% reduction in amyloid-beta suggests multiple clearance routes may be at work simultaneously.
If microglia are indeed being activated to consume and degrade plaques directly, that would represent a second major mechanism of action, which could make the compound even more valuable.
Future studies will need to verify these findings in larger models, map the precise biological pathways involved, and eventually test the compound in early symptomatic Alzheimer’s patients in human clinical trials.
The researchers describe the current findings as establishing a strong foundation for exploring biometal therapies as a new class of Alzheimer’s treatments.
That is measured, cautious language, and it is the right kind of language to use at this stage of the science.
But behind that caution is something genuinely exciting: a compound that fixes the brain’s broken drain, clears nearly half the toxic buildup that defines Alzheimer’s disease, and restores measurable memory function, while already having a human safety record that could accelerate its path to the clinic.
In a field where progress has often been painfully slow, that combination is rare.
A Different Way of Thinking About Memory Loss
Alzheimer’s research has spent decades focused on what builds up in the brain.
This study invites a different question: what if the more important problem is what fails to leave?
The blood-brain barrier is not just a security fence keeping dangerous things out.
It is also an active export system, constantly clearing waste that the brain produces as a natural byproduct of its own activity.
When that export system fails, the consequences compound over years and decades until they become visible as memory loss, confusion, and eventually the complete erosion of the person within.
Cu(ATSM) does not claim to cure Alzheimer’s disease.
No single study and no single compound can do that.
What it does is point toward an underexplored treatment strategy: restoring the brain’s own capacity to protect itself, rather than only trying to clean up after the damage has already accumulated.
That idea is worth thinking about carefully, because if it holds up in human trials, it could change not just how we treat Alzheimer’s, but how early we might one day intervene.
The Human Safety Trail Already Exists, And It Started With A Different Disease
Here is the part of this story that almost nobody is talking about yet.
Cu(ATSM) did not begin its life as an Alzheimer’s drug.
It began as a Parkinson’s disease candidate.
Back in August 2017, a company called Collaborative Medicinal Development started a Phase 1 dose finding trial of Cu(ATSM) in patients with early Parkinson’s disease.
The trial design was methodical and cautious, exactly what you would want for a compound moving into human bodies for the first time.
Patients received daily oral doses for 28 days, in small groups of six, with each new group testing a slightly higher dose than the last.
Researchers tracked blood chemistry, vital signs, and serum metal levels every single week.
Some patients who appeared to benefit were allowed to continue for up to six full treatment cycles.
That trial did not happen in isolation either.
Before researchers gave Cu(ATSM) to Parkinson’s patients, they ran it through a Phase 1 study in people with ALS first, and only moved to the Parkinson’s cohort after the early ALS dose groups cleared safety checks.
In other words, this molecule has already walked through two separate gauntlets of human nervous system disease trials.
That is the part of the story that changes the math for Alzheimer’s.
Why This Timeline Detail Actually Matters
Most experimental Alzheimer’s drugs spend years, sometimes a full decade, in the earliest stages of human testing before anyone knows if they are even safe to keep testing.
Phase 1 trials exist purely to answer one question: will this hurt people?
Cu(ATSM) has already cleared that question for two other brutal neurodegenerative diseases.
According to a research and development summary from the Michael J. Fox Foundation, which has funded ongoing optimization of the compound, the early studies found no findings from preclinical safety testing that would block further clinical development.
That is a meaningfully different starting position than a brand new molecule walking into its first human trial cold.
It does not guarantee Cu(ATSM) will work for Alzheimer’s.
Safety in one disease context does not equal safety in another, and dosing requirements can shift depending on what the drug needs to accomplish in the brain.
But it does mean the regulatory runway is shorter, and shorter runways matter enormously in a disease that currently kills people faster than research can keep up.
The PET Imaging Clue Nobody Expected
There is another detail buried in the Parkinson’s research that deserves more attention.
Early imaging studies using a radioactive form of the compound, called [62Cu]ATSM, showed that it delivers copper directly and selectively into the striatum, a brain region damaged in Parkinson’s disease.
Even more interesting, the amount of copper that accumulated there correlated with how severe a patient’s disease already was.
That tells researchers something important: the compound is not randomly diffusing through brain tissue.
It is being drawn toward the exact regions where neurological damage is occurring, almost like a homing signal toward distressed tissue.
If that same targeting behavior holds true in Alzheimer’s, it could explain why the Monash team saw such a dramatic jump in copper concentration specifically within the brain’s microvessels, the tiny blood vessels that make up the blood-brain barrier.
A Crowded Field, But A Different Lane
It helps to understand just how packed the Alzheimer’s drug development pipeline already is right now.
Dozens of compounds are moving through trials at any given time, most of them chasing the same basic strategy of attacking amyloid plaques directly with antibodies.
Lecanemab and donanemab proved that approach can work, at least partially, which is why both received regulatory approval in recent years.
But both drugs also carry real risks, including brain swelling and microbleeds, and both require regular infusions and intensive monitoring through MRI scans.
Cu(ATSM) is not trying to compete in that same lane.
It is not an antibody, it does not require infusions, and based on the Parkinson’s trial data, it can potentially be taken as a daily oral dose.
That alone would represent a meaningful quality of life difference for patients and caregivers managing a disease that already strips away independence in painful increments.
What An Oral Daily Pill Would Actually Mean
It is worth pausing on this point because it tends to get lost in the science.
Antibody infusion drugs require patients to travel to infusion centers, often every two to four weeks, accompanied by a caregiver, for hours at a time.
For aging patients already struggling with mobility, memory, and independence, that logistical burden is enormous.
A daily oral medication, even one requiring regular blood monitoring, removes a significant amount of that burden.
It also opens the door to earlier and more widespread use, since oral medications are generally easier to scale to large patient populations than infusion therapies that require specialized clinical infrastructure.
None of this is guaranteed yet for Cu(ATSM) in Alzheimer’s specifically.
The current findings are still confined to a mouse model, and translating any compound from mice to humans introduces variables that cannot be fully predicted in advance.
Copper’s Complicated Reputation In Neuroscience
There is one more layer of nuance worth understanding here, because copper has a strange dual reputation in brain science.
For years, some researchers suspected that excess copper might actually contribute to Alzheimer’s pathology rather than help it, based on studies showing copper dysregulation in affected brain tissue.
That apparent contradiction is part of why Cu(ATSM) is interesting from a chemistry standpoint.
The compound is specifically engineered to behave differently from free copper ions floating loosely in tissue.
Its chemical structure allows it to release copper selectively inside cells that are under metabolic stress, rather than dumping copper indiscriminately throughout brain tissue.
That selective release mechanism is part of what separates a designed therapeutic compound from simply taking a copper supplement, and it is also why researchers describe this as biometal modulation rather than simple copper supplementation.
The Bigger Picture For Patients And Families Watching This Space
If you are someone watching a parent or spouse navigate Alzheimer’s right now, it is worth holding two truths at once.
The first truth is that this finding is genuinely exciting, and the existing human safety data on Cu(ATSM) gives it a real, tangible advantage over most experimental compounds at this stage.
The second truth is that no human Alzheimer’s trial has been announced yet, and even if one begins soon, meaningful efficacy data in human patients is still likely years away.
Holding both of those truths at the same time, without collapsing into either blind optimism or dismissiveness, is probably the healthiest way to follow this kind of research as it develops.
Science rarely moves in a straight line, and breakthroughs in mice do not always survive contact with human biology.
But every so often, a compound shows up with both a compelling mechanism and a head start on safety testing, and that combination is rare enough to pay attention to.
This may be one of those moments.
The next year of research will tell us a great deal about whether it actually is.
References and Further Reading
Copper drug restores memory and clears toxic Alzheimer’s proteins, Monash University, June 2026
2026 Alzheimer’s Disease Facts and Figures, Alzheimer’s Association
